Manuscript Details

Manuscript number	APPETITE_2019_330_R1
Title	Exploration of associations between the FTO rs9939609 genotype, fasting and postprandial appetite-related hormones and perceived appetite in healthy men and women
Article type	Full Length Article

Abstract

Background: The fat mass and obesity-associated gene (FTO) rs9939609 A-allele has been associated with obesity risk. Although the exact mechanisms involved remain unknown, the FTO rs9939609 A-allele has been associated with an impaired postprandial suppression of appetite. Objectives: To explore the influence of FTO rs9939609 genotype on fasting and postprandial appetite-related hormones and perceived appetite in a heterogeneous sample of men and women. Design: 112 healthy men and women aged 18-50-years-old completed three laboratory visits for the assessment of FTO rs9939609 genotype, body composition, aerobic fitness, resting metabolic rate, visceral adipose tissue, liver fat, fasting leptin, and fasting and postprandial acylated ghrelin, total PYY, insulin, glucose and perceived appetite. Participants wore accelerometers for seven consecutive days for the assessment of physical activity and sedentary behaviour. Multivariable general linear models quantified differences between FTO rs9939609 groups for fasting and postprandial appetite outcomes, with and without the addition of a priori selected physiological and behavioural covariates. Sex-specific univariable Pearson's correlation coefficients were quantified between the appetite-related outcomes and individual characteristics. Results: 95% confidence intervals for mean differences between FTO rs9939609 groups overlapped zero in unadjusted and adjusted general linear models for all fasting ($P \geq 0.28$) and postprandial ($P \geq 0.19$) appetite-related outcomes. Eta2 values for explained variance attributable to FTO rs9939609 were <5% for all outcomes. An exploratory correlation matrix indicated that associations between fasting and postprandial acylated ghrelin, total PYY and general or abdominal adiposity were also small ($r = -0.23$ to 0.15, $P \geq 0.09$). Fasting leptin, glucose and insulin and postprandial insulin concentrations were associated with adiposity outcomes ($r = 0.29$ to 0.81, $P \leq 0.033$). Conclusions: Associations between the FTO rs9939609 genotype and fasting or postprandial appetite-related outcomes were weak in healthy men and women.

Keywords	FTO; appetite; ghrelin; PYY; hunger.
Taxonomy	Sex-based Differences on Appetite, Appetite Assessment
Manuscript category	Physiology and Metabolism

Corresponding Author	David Stensel
Corresponding Author's Institution	Loughborough University
Order of Authors	Fernanda R. Goltz, Alice Thackray, veronica varela mato, James King, James Dorling, Monika Dowejko, Sarabjit Mastana, Julie Thompson, Greg Atkinson, David Stensel
Suggested reviewers	Miriam Glegg, Andy Blannin, James Betts

Submission Files Included in this PDF

File Name [File Type]

Response to reviewers.docx [Response to Reviewers]

Abstract.docx [Abstract]

Revised manuscript.docx [Manuscript File]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

Research Data Related to this Submission

There are no linked research data sets for this submission. The following reason is given:
Data will be made available on request

Dear Dr. Appelhans,

RE: APPETITE_2019_330

18/05/2019

We would like to thank the reviewers for giving their time to carefully examine our manuscript. Our research team are delighted to be given the opportunity to revise our manuscript for additional consideration by *Appetite*. Please find below a list of point-by-point responses to the comments raised by the reviewers. For clarity, changes to the manuscript have been highlighted in yellow. We hope that we have interpreted these comments accurately and that our responses and manuscript modifications are satisfactory.

We look forward to hearing about our paper in due course.

Yours sincerely,

Professor David Stensel
Professor of Exercise Metabolism
School of Sport, Exercise and Health Sciences
Loughborough University
Leicestershire
LE11 3TU, UK
Phone: +44(0)1509 226344
Email: D.J.Stensel@lboro.ac.uk

Reviewer one:

Comment #1: The manuscript aims "to explore the influence of the FTO genotype on fasting and postprandial appetite-related hormones and perceived appetite in heterogeneous sample of men and women". The study is innovative and current, but presents some important problems that should be reviewed.

Author response #1: We thank the reviewer for the kind comment on the novelty of our study and we hope our responses below and the modifications in the manuscript address the comments raised.

Comment #2: Line 2 - the authors need to put the "rs" of the FTO gene that was studied, considering that there are several "rs" in the scientific literature. Do not just put "risk AA genotype".

Author response #2: We have specified the "rs" of the FTO gene throughout the manuscript, including the title and the abstract.

Comment #3: Line 4 - The authors said that the study population was heterogeneous, but they were all adults. Therefore, the age difference of the research volunteers should be expected when it is proposed to evaluate adults without limiting the age group.

Author response #3: We recruited men and women aged between 18 and 50 years old. We have included this information in the abstract for clarity as follows:

Abstract, page 2, lines 32-35: 112 healthy men and women aged 18-50 years old completed three laboratory visits for the assessment of FTO rs9939609 genotype, body composition, aerobic fitness, resting metabolic rate, visceral adipose tissue, liver fat, fasting leptin, and fasting and postprandial acylated ghrelin, total PYY, insulin, glucose and perceived appetite.

Comment #4: Introduction: Paragraph 4 - the authors described ghrelin, adipose tissue, physical activity .... and specifically spoke of ghrelin in obese people. Were the other variables described in the paragraph observed in eutrophic or obese people? The behavior of several indicators described differ between eutrophic and obese. In addition, the study evaluated eutrophic.

Author response #4: Our study included participants with a wide range of adiposity, from normal weight to obesity (BMI range from 18.4 to 40.3 $kg \cdot m^{-2}$, as described in Table 1). The wide range of adiposity enabled us to evaluate whether adiposity was associated with the appetite-related outcomes of interest. The evidence highlighted in the fourth paragraph of the introduction is an overview of potential factors that can influence appetite. We have specified for each study cited whether the study sample included individuals with normal weight, overweight or obesity, as follows:

Introduction, page 4, lines 90-106: Data from previous studies have indicated that women exhibit higher fasting concentrations of acylated ghrelin than men in those who were lean

(Alajmi et al. 2016; Douglas et al. 2017) and in those who were overweight/obese (Douglas et al. 2017). Furthermore, an inverse relationship between general adiposity levels and fasting ghrelin levels has been suggested in study samples including individuals who were lean and individuals who were obese, possibly because of elevated insulin or leptin levels (Tschöp et al. 2001; Shiiya et al. 2002; Sondergaard et al. 2009). Individuals who are obese also exhibit a reduced postprandial suppression of ghrelin (Le Roux et al. 2005) and blunted postprandial increases in PYY (Le Roux et al. 2006). Limited evidence has also suggested an inverse association between visceral adipose tissue and fasting ghrelin levels in women who were lean and women who were obese, likely caused by substances secreted by visceral adipocytes, such as TNFα and leptin (Sondergaard et al. 2009). Moreover, fat-free mass, as the largest contributor to resting metabolic rate, has been identified as a key driver of appetite and energy intake in individuals who were lean and in individuals who were obese (Blundell et al. 2015b). In a systematic review including studies in individuals with normal weight, overweight or obesity, physical activity has also been suggested to alter the sensitivity of the appetite control system by enhancing meal-induced satiety which may facilitate energy balance over the long term (Beaulieu et al. 2016).

Comment #5: Objective: The second objective proposed " to explore potential associations between fasting and postprandial appetite outcomes and physiological and behavioral characteristics" was not completely answered in the results and conclusion. The results of the first objective are in table 1, figure 1, table 2 and table 3. In table 4, the authors associate fasting insulin, glucose and leptin with anthropometrics, metabolic and physical active parameters.

Author response #5: The second objective of the study is answered in the results section in page 17, lines 326 to 357, where all sex-specific Pearson's correlation coefficients between appetite-related outcomes and individual characteristics are summarised. Table 4 highlights where significant correlations were observed, namely the correlations between the individual characteristics and fasting insulin, glucose and leptin. Additionally, this objective is also addressed in the discussion section on lines 374-376 and on lines 465-499. Nevertheless, we have included a sentence in the conclusion of the manuscript which answers the second objective directly, as follows:

Discussion, page 24, lines 530-532: The associations between fasting and postprandial acylated ghrelin, total PYY and general or abdominal adiposity were also small, while fasting leptin, glucose and insulin and postprandial insulin concentrations were consistently and positively associated with adiposity outcomes.

Comment #6: Participants: Why did the authors add 1% of blacks people in the study sample? It is well known that blacks people have different body composition and energy metabolism than White Europeans and Asians. Why did they not exclude blacks people? This sample is not representative of the race.

Author response #6: We did not recruit participants based on ethnicity as it was expected that the vast majority of the study sample would be white Europeans, considering the general

population where the study was conducted. Excluding participants of black or Asian ethnicity did not alter the interpretation of our findings and, therefore, it was preferred to maintain the original study sample in order to increase the statistical power of our analyses.

Comment #7: Preliminary testing: Why did you use three skinfolds to estimate body composition? It is a doubly indirect method for estimating body composition.

Author response #7: We appreciate the reviewer's comment and we agree that skinfolds is an indirect method to estimate body composition which presents inherent limitations. However, we did not have access to other more accurate methods of assessing total body fat in such a large sample (e.g. BOD POD, DEXA). It is known that, when performed by a trained and experienced examiner, skinfold measurements can provide a reliable estimation of body fat mass. Additionally, we used body fat mass estimated by skinfolds in conjunction with BMI and body fat distribution assessed with high-quality MRI scans (visceral adipose tissue, abdominal subcutaneous adipose tissue and liver fat). Our approach of using three skinfold sites was based on the equation which has been validated for the population we recruited for the study. We have included a sentence in the methods section of the manuscript to highlight the care taken for the consistency of skinfold measurements, as follows:

Methods, page 5, lines 137-138: All skinfold measurements were performed by the same experienced examiner throughout the study.

Comment #8: Blood sampling and biochemical analysis - paragraph 1 - lines 9 and 10 - the authors describe "haemoglobin concentrations and hematocrit", but did not show results of these analysis.

Author response #8: Haemoglobin concentration and haematocrit were assessed to ensure any changes in plasma volume did not affect the quantification of blood parameters. As no exercise was performed during the study visit where blood samples were collected, we did not expect to observe any significant plasma volume changes and these analyses were performed for reassurance only. We have clarified that "Correction of blood parameter concentrations for acute changes in plasma volume had a negligible influence on our findings and, therefore, the unadjusted plasma concentrations are displayed for simplicity" in the statistical analysis section (Methods, page 9, lines 247-249).

Comment #9: Statistical analysis: The Hardy-Weinberg equilibrium was calculated?

Author response #9: We have calculated the genetic variation of our population using the Hardy-Weinberg equation and can confirm there was no significant deviation from Hardy-Weinberg equilibrium. This information has been added to the methods as indicated below. Furthermore, the prevalence of the three FTO rs9939609 genotypes in our study sample was similar to the prevalence reported previously by Frayling et al. 2007 in 13 cohorts with 38,759 participants: 16% of the population as AA (19% in our study), 37% as TT (36% in our study) and 47% as AT (45% in our study).

Methods, page 8, lines 219-221: Genotype frequency of FTO rs9939609 was assessed using a goodness-of-fit chi-square test and did not deviate from Hardy-Weinberg equilibrium (χ^2 = 0.435, P = 0.509).

Comment #10: Participants characteristics: lines 3-5 - results are expected and do not need be discussed in detail.

Author response #10: The sentence summarizing the differences observed between men and women was removed from the text, as requested by the reviewer.

Comment #11: Figure 1 - results are not innovative, but I recommend that you keep the figure. It would be important to add the p-value in the figures.

Author response #11: We have kept the figure and highlighted where the P-value was lower than 0.05 between males and females.

Comment #12: Sex-specific Pearson - We lacked discussing the result of the insulin ratio with VO2 and glucose with VO2. The authors could talk in the context of energy metabolism.

Author response #12: We have now highlighted the associations between insulin and glucose with V□O_2 peak in the discussion section, as follows:

Discussion, pages 22-23, lines 484-488: Additionally, negative associations between V□O_2 peak and fasting and postprandial insulin, fasting glucose and fasting leptin were observed. Acute and chronic exercise augments insulin sensitivity by increasing insulin-like growth factor 1, and individuals with higher cardiorespiratory fitness typically show higher insulin sensitivity (Borghouts and Keizer, 2000; Castro et el. 2016).

Comment #13: Table 4 is extensive, with many correlations already expected. In addition, it was not the objective of the study. I suggest a careful review of the results for table 4! Many correlations were already expected and need not be highlighted. I suggest highlighting the correlations necessary to respond to the objectives proposed in the study.

Author response #13: Table 4 was included in order to summarize the significant associations observed between fasting insulin, glucose and leptin and individual characteristics, which answers the second objective of the study i.e. to explore potential associations between fasting and postprandial appetite outcomes and physiological and behavioural characteristics. However, the table can be included as supplementary online material if deemed appropriate by the reviewer and/or editor.

Comment #14: Discussion:
Paragraph 1 – line 11 - The authors said that they evaluated "lifestyle characteristics", but only the physical activity practice was evaluated.

Author response #14: We used the term 'lifestyle characteristics' to summarize the measurements of both habitual physical activity levels and sitting time.

Comment #15: Paragraph 2 - line 11 - the authors refer to "heterogeneous samples" to justify the difference of the results found in the present study and in Karra et al (2013). Does age influence the relationship of ghrelin to appetite?

Author response #15: Our sample was heterogeneous not only in terms of age, but also in adiposity parameters (as shown in Table 1), as well as including both males and females. On the contrary, the study performed by Karra et al. only included healthy young lean males with an average age of ~23 years. These differences in study samples might explain differences in the observed results, as previous evidence indicates ghrelin levels can vary between males and females and also according to body adiposity (as indicated in the manuscript's introduction). Additionally, although evidence is limited, it has been suggested that the loss of appetite and decline in energy intake in older adults may be related to the concomitant elevation in circulating leptin and insulin and a reduction in ghrelin concentrations (Landi et al. Nutrients, 2016;8(2):69). We have clarified that the study of Karra et al. included only lean young males in the discussion section, as follows:

Discussion, pages 19-20, lines 389-391: Differences between study samples can possibly explain discrepancies between findings, as Karra et al. (2013) recruited healthy young lean males, while our sample was composed of a heterogeneous group of males and females.

Comment #16: I would suggest adding also a result of a recent study published with obese women in which "Participants with the AA genotype had lower values than those with TT and TA in the postprandial period." (Magno et al. , 2018).

Author response #16: We appreciate the reviewer's suggestion and the reference to the study performed by Magno is included in the discussion section (page 20, lines 393-397).

Comment #17: Paragraph 3 - line 10 - review use of numbers 3-36 subscript!

Author response #17: We have presented '3-36' in subscript to indicate the form of PYY that was measured in the study by Karra et al. (2013). PYY3-36 is commonly reported in the literature with 3-36 presented in subscript; therefore, we feel 'PYY_{3-36}' will be familiar to the reader.

Comment #18: Paragraph 6 - line 3 - review "women had significantly lower fat mass and fat free mass" because women had higher fat mass. See table 1!

Author response #18: The sentence highlighted by the reviewer reads "It should be noted that all participants received an identical standardised meal and, as women had significantly lower body mass and fat free mass, and consequently lower resting metabolic rate, it was expected that the postprandial suppression of appetite would be stronger in women.". We have not

mentioned fat mass in this sentence but highlighted that both body mass and fat free mass were lower in women than men which is supported by the data presented in Table 1.

Comment #19: Conclusion: The conclusion does not address the second objective proposed by the authors (association between fasting and postprandial appetite with physiological and behavioral characteristics).

Author response #19: We have included a sentence in the conclusion of the manuscript which answers the second objective of the study, as follows:

Discussion, page 24, lines 530-532: The associations between fasting and postprandial acylated ghrelin, total PYY and general or abdominal adiposity were also small, while fasting leptin, glucose and insulin and postprandial insulin concentrations were consistently and positively associated with adiposity outcomes.

Comment #20: References: The references of Carvalho et al (2018) and Melhorn et al (2018) were not found. Please review all other references!

Author response #20: We thank the reviewer for bringing this to our attention. All references have been reviewed accordingly.

Reviewer two:

Comment #1: In the current manuscript the authors seek to understand the role of the obesity-associated gene FTO on behavioral feeding phenotype and associated physiologic and metabolic parameters. Specifically multiple indices of appetite, feeding peptide levels in plasma (in fasted and fed state), fitness and metabolic rate in healthy and FTO-identified patients were performed. This is achieved through a combination of laboratory visits and data obtained from an accelerometer that patients wore while away from the lab. The authors should be commended on this effort. This topic is relevant to the field of obesity research and associated feeding pathologies. I offer my constructive criticisms here.

Author response #1: We thank the reviewer for the positive comments on our manuscript and we hope that the helpful comments below have been addressed appropriately.

Comment #2: I appreciate the care taken to measure acylated ghrelin across fed and fasted states. However cephalic ghrelin secretion in anticipation of meals was not measured. I bring this up because normalizing each patient by fasting does not evaluate conditioned or pre-meal ghrelin responses associated with anticipation of food. I think this should be qualified in the discussion.

Author response #2: We presented the appetite and plasma concentrations of acylated ghrelin, total PYY, insulin and glucose relative to baseline values (i.e., delta) to minimise the potential influence of day-to-day biological variability in these outcomes. However, given that participants knew when the meal would be provided, we cannot rule out that a preprandial increase in ghrelin may reflect an anticipatory signal for food intake rather than initiating meal intake (e.g., Cummings et al. 2001 Diabetes, 50: 1714-1719; Frecka & Mattes 2008 Am J Physiol Gastrointest Liver Physiol, 294: G699-707). Therefore, we have included this in the discussion section as follows:

Discussion, page 24, lines 522-526: Furthermore, participants were aware of the meal timing so it is possible that the higher preprandial ghrelin concentrations reflected an anticipatory response to impending meal intake (Cummings et al. 2001). Future studies should consider isolating meal provision from time-related cues and/or examining the influence of cephalic phase ghrelin release during meal anticipation on postprandial appetite responses.

Comment #3: Is it possible that a laboratory setting is not appropriate to measure FTO X obeseogenic food environment interactions known to promote maladaptive physiologic responses that induce obesity? Given the lack of interactions it would seem suitable to mention this in the discussion inline with targeted weight loss for example.

Author response #3: We thank the reviewer for raising this point. The aim of our study was to determine the influence of the FTO rs9969309 genotype on fasting and postprandial appetite-related hormones and, therefore, it was important to study participants in a controlled environment and in response to a standardised meal to minimise the influence of any potential confounding factors. However, we agree that the laboratory setting may not be appropriate to

determine the effect of the FTO rs9939609 genotype on food choice and eating behavior and we have highlighted this as a limitation and potential future direction in the discussion as follows:
Discussion, pages 23-24, lines 518-521: Additionally, it is possible that a study design where individuals are exposed to an obesigenic food environment, such as an *ad libitum* buffet meal rather than a standardised meal stimulus, may be more appropriate to elucidate the effect of the FTO rs9939609 genotype on food choice and eating behaviour

Comment #4: Separate from physiologic responses, psychological process are also regulators of food intake. For example, Dang et al. 2018, recently reported that AA individuals have higher food craving than controls, supporting the contention that in some cases food reward mechanisms may contribute to body weight gain in FTO individuals. Although the authors did not set out to test this aspect of feeding behavior, the discussion of physiologic versus psychological mechanisms would strengthen the conclusion.

Author response #4: We thank the reviewer for the suggestion and we have included the findings from Dang et al. in the discussion section as well as highlighting the importance of assessing psychological factors in future studies in the conclusion, as follows:

Discussion, page 20, lines 418-420: Moreover, recent evidence suggests that AA individuals show higher total food cravings, compared to TT individuals, which correlated with BMI (Dang et al. 2018).

Discussion, page 24, lines 532-534: Further research is needed to clarify the precise role of the FTO rs9939609 genotype in moderating appetite control and energy intake, including both physiological and psychological factors that influence eating behaviour.

Exploration of associations between the FTO rs9939609 genotype, fasting and postprandial appetite-related hormones and perceived appetite in healthy men and women

Fernanda R. Goltz [1,2], Alice E. Thackray [1,2], Veronica Varela-Mato [1], James A. King [1,2], James L. Dorling [3], Monika Dowejko [1], Sarabjit Mastana [1], Julie Thompson [1,2], Greg Atkinson [4], David J. Stensel [1,2]

ABSTRACT

Background: The fat mass and obesity-associated gene (FTO) rs9939609 A-allele has been associated with obesity risk. Although the exact mechanisms involved remain unknown, the FTO rs9939609 A-allele has been associated with an impaired postprandial suppression of appetite. **Objectives:** To explore the influence of FTO rs9939609 genotype on fasting and postprandial appetite-related hormones and perceived appetite in a heterogeneous sample of men and women. **Design:** 112 healthy men and women aged 18-50-years-old completed three laboratory visits for the assessment of FTO rs9939609 genotype, body composition, aerobic fitness, resting metabolic rate, visceral adipose tissue, liver fat, fasting leptin, and fasting and postprandial acylated ghrelin, total PYY, insulin, glucose and perceived appetite. Participants wore accelerometers for seven consecutive days for the assessment of physical activity and sedentary behaviour. Multivariable general linear models quantified differences between FTO rs9939609 groups for fasting and postprandial appetite outcomes, with and without the addition of *a priori* selected physiological and behavioural covariates. Sex-specific univariable Pearson's correlation coefficients were quantified between the appetite-related outcomes and individual characteristics. **Results:** 95% confidence intervals for mean differences between FTO rs9939609 groups overlapped zero in unadjusted and adjusted general linear models for all fasting ($P \geq 0.28$) and postprandial ($P \geq 0.19$) appetite-related outcomes. Eta^2 values for explained variance attributable to FTO rs9939609 were <5% for all outcomes. An exploratory correlation matrix indicated that associations between fasting and postprandial acylated ghrelin, total PYY and general or abdominal adiposity were also small (r = -0.23 to 0.15, $P \geq 0.09$). Fasting leptin, glucose and insulin and postprandial insulin concentrations were associated with adiposity outcomes (r = 0.29 to 0.81, $P \leq 0.033$). **Conclusions:** Associations between the FTO rs9939609 genotype and fasting or postprandial appetite-related outcomes were weak in healthy men and women.

Keywords: FTO, appetite, ghrelin, PYY, hunger.

Exploration of associations between the FTO rs9939609 genotype, fasting and postprandial appetite-related hormones and perceived appetite in healthy men and women

Fernanda R. Goltz [1,2], Alice E. Thackray [1,2], Veronica Varela-Mato [1], James A. King [1,2], James L. Dorling [3], Monika Dowejko [1], Sarabjit Mastana [1], Julie Thompson [1,2], Greg Atkinson [4], David J. Stensel [1,2]

[1] National Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.

[2] University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, United Kingdom.

[3] Ingestive Behavior Laboratory, Pennington Biomedical Research Center, Baton Rouge, United States.

[4] School of Health and Social Care, Teesside University, Middlesbrough, United Kingdom.

Corresponding author:

Professor David Stensel

School of Sport, Exercise and Health Sciences

Loughborough University

Leicestershire

LE11 3TU

United Kingdom

Phone: +44(0)1509 226344, Fax: +44(0)1509 226301, E-mail: D.J.Stensel@lboro.ac.uk

Declarations of interest: None.

ABSTRACT

Background: The fat mass and obesity-associated gene (FTO) rs9939609 A-allele has been associated with obesity risk. Although the exact mechanisms involved remain unknown, the FTO rs9939609 A-allele has been associated with an impaired postprandial suppression of appetite. **Objectives:** To explore the influence of FTO rs9939609 genotype on fasting and postprandial appetite-related hormones and perceived appetite in a heterogeneous sample of men and women. **Design:** 112 healthy men and women aged 18-50-years-old completed three laboratory visits for the assessment of FTO rs9939609 genotype, body composition, aerobic fitness, resting metabolic rate, visceral adipose tissue, liver fat, fasting leptin, and fasting and postprandial acylated ghrelin, total PYY, insulin, glucose and perceived appetite. Participants wore accelerometers for seven consecutive days for the assessment of physical activity and sedentary behaviour. Multivariable general linear models quantified differences between FTO rs9939609 groups for fasting and postprandial appetite outcomes, with and without the addition of *a priori* selected physiological and behavioural covariates. Sex-specific univariable Pearson's correlation coefficients were quantified between the appetite-related outcomes and individual characteristics. **Results:** 95% confidence intervals for mean differences between FTO rs9939609 groups overlapped zero in unadjusted and adjusted general linear models for all fasting ($P \geq 0.28$) and postprandial ($P \geq 0.19$) appetite-related outcomes. Eta^2 values for explained variance attributable to FTO rs9939609 were <5% for all outcomes. An exploratory correlation matrix indicated that associations between fasting and postprandial acylated ghrelin, total PYY and general or abdominal adiposity were also small (r = -0.23 to 0.15, $P \geq 0.09$). Fasting leptin, glucose and insulin and postprandial insulin concentrations were associated with adiposity outcomes (r = 0.29 to 0.81, $P \leq 0.033$). **Conclusions:** Associations between the FTO rs9939609 genotype and fasting or postprandial appetite-related outcomes were weak in healthy men and women.

Keywords: FTO, appetite, ghrelin, PYY, hunger.

INTRODUCTION

The scientific understanding of appetite control has increased considerably in recent decades, which has been helpful in elucidating the complex nature of energy balance and weight control. Central components of the homeostatic control of appetite comprise signals from adipose tissue and peptide hormones secreted from the digestive tract, which act acutely and/or chronically on central neural pathways to influence hunger, satiety and subsequent energy intake (MacLean et al. 2017). These signals and hormones include the tonic signals leptin and insulin that regulate long-term changes in energy balance and adiposity status, as well as a variety of episodic gut signals, which mediate hunger and satiety on a meal-by-meal basis (Blundell et al. 2008, 2015a; MacLean et al. 2017). Notable among the episodic mediators of appetite and energy intake are acylated ghrelin and peptide YY (PYY) which exert orexigenic and anorexigenic effects, respectively, to facilitate meal initiation and termination (Neary and Batterham, 2009).

Over the last 16 years, our laboratory has measured circulating concentrations of appetite-related hormones in response to meal ingestion in many studies. A consistent observation from this body of work is the degree of variability in responses observed between participants studied under identical conditions. Furthermore, using the "gold standard" replicated crossover study design (Atkinson and Batterham, 2015; Senn, 2016), we have demonstrated recently the presence of true interindividual heterogeneity in appetite perceptions and circulating concentrations of acylated ghrelin, total PYY, insulin and glucose in response to a standardised meal, over and above any random within-subject variability and measurement error (Goltz et al. 2019). Similar findings were also observed in acylated ghrelin, total PYY and perceived appetite responses to replicated single bouts of aerobic exercise (Goltz et al. 2018).

The factors responsible for interindividual variability in appetite-related hormone concentrations are not fully understood, but it is plausible that differences in individual characteristics and behaviours may contribute to the variability observed. In this regard, the fat mass and obesity-associated gene (FTO) has been associated with obesity risk, with individuals homozygous for the A allele (AA) of FTO rs9939609 having a 1.7-fold higher obesity risk than individuals homozygous for the T allele (TT) (Frayling et al. 2007). Although the exact mechanisms through which FTO rs9939609 influences fat mass accumulation remain unknown, it has been suggested that it exerts its effect on food intake rather than on energy expenditure (Speakman et al. 2008). Furthermore, rs9939609 AA individuals have been shown to exhibit an attenuated postprandial suppression of hunger and acylated ghrelin compared with TT individuals, which may

predispose AA individuals to higher energy intake and, consequently, higher fat mass (Karra et al. 2013). However, the study by Karra and colleagues was performed in young healthy weight males and it is not known whether this influence of the FTO rs9939609 gene on postprandial appetite regulation is observed in a heterogenous sample of men and women.

Beyond genetic influence, it has been speculated that other individual factors may affect appetite regulation. Data from previous studies have indicated that women exhibit higher fasting concentrations of acylated ghrelin than men in those who were lean (Alajmi et al. 2016; Douglas et al. 2017) and in those who were overweight/obese (Douglas et al. 2017). Furthermore, an inverse relationship between general adiposity levels and fasting ghrelin levels has been suggested in study samples including individuals who were lean and individuals who were obese, possibly because of elevated insulin or leptin levels (Tschöp et al. 2001; Shiiya et al. 2002; Sondergaard et al. 2009). Individuals who are obese also exhibit a reduced postprandial suppression of ghrelin (Le Roux et al. 2005) and blunted postprandial increases in PYY (Le Roux et al. 2006). Limited evidence has also suggested an inverse association between visceral adipose tissue and fasting ghrelin levels in women who were lean and women who were obese, likely caused by substances secreted by visceral adipocytes, such as TNFα and leptin (Sondergaard et al. 2009). Moreover, fat-free mass, as the largest contributor to resting metabolic rate, has been identified as a key driver of appetite and energy intake in individuals who were lean and in individuals who were obese (Blundell et al. 2015b). In a systematic review including studies in individuals with normal weight, overweight or obesity, physical activity has also been suggested to alter the sensitivity of the appetite control system by enhancing meal-induced satiety which may facilitate energy balance over the long term (Beaulieu et al. 2016). Together, these findings highlight the importance of investigating the effect of the FTO rs9939609 gene on appetite parameters in a sample of males and females with a wide range of age, adiposity and physical activity levels, including physiological and behavioural characteristics as covariates in the analyses.

The primary aim of this study was to use objective assessment methods in order to explore the influence of the FTO rs9939609 genotype on fasting and postprandial appetite-related hormones and perceived appetite in a sample of healthy men and women. The secondary aim was to explore potential associations between fasting and postprandial appetite outcomes and physiological and behavioural characteristics.

METHODS

Participants

With the approval of the University Ethics Advisory Sub-Committee, a total of 121 participants (57 men, 64 women) aged 18 to 50 years provided written informed consent before taking part in the study. All participants were deemed to be stable in their body mass (≤ 3 kg change in the previous 3 months), non-smokers, habitual breakfast eaters, had no history of cardiovascular or metabolic disease, and were not dieting or taking any medications known to influence the outcome measures. Female participants were premenopausal and postmenopausal and not pregnant. Nine participants withdrew from the study before completing all study measurements due to time constraints. Therefore, data are presented for 112 participants (56 men, 56 women) in this manuscript. The study sample self-reported ethnicity distribution was as follows: 93% white Europeans, 6% Asians and 1% black.

Visit 1: Preliminary testing

Participants attended the laboratory for a preliminary visit to confirm eligibility, and to undergo familiarisation, anthropometric measurements and determination of peak oxygen uptake ($V\square O_2$ peak). The eligibility assessment included screening questionnaires to assess health status and food preferences and/or restrictions. Stature was measured to the nearest 0.1 cm and body mass to the nearest 0.1 kg using an electronic measuring station (Seca, Hamburg, Germany), and body mass index (BMI) was calculated. The sum of three skinfolds (chest, abdomen and thigh for men, and triceps, suprailiac and thigh for women) was used to estimate body density (Jackson and Pollock 1978, 1980) and body fat percentage (Siri, 1961). All skinfold measurements were performed by the same experienced examiner throughout the study. Waist circumference was measured as the narrowest point between the lower rib margin and the iliac crest.

Participants were familiarised with walking and running on the treadmill (Technogym Excite Med, Cesena, Italy) before completing an incremental uphill treadmill protocol to determine $V\square O_2$ peak. The participants ran at a fixed individualised speed (4.5 to 14.0 $km \cdot h^{-1}$), with the initial gradient of the treadmill set to 0%. The treadmill gradient was increased by 1% every minute until volitional exhaustion. Heart rate was monitored continuously using short-range telemetry (Polar A3, Kempele, Finland), and ratings of perceived exertion (Borg, 1973) were recorded at the end of each minute. Expired air samples were monitored continuously using a breath-by-breath gas analysis system (Cortex Metalyser 3B, Leipzig, Germany). An average of

the breath-by-breath oxygen uptake data was taken every 10 s, and V□O_2 peak was defined as the highest 30 s rolling average.

Visit 2: Magnetic resonance imaging (MRI) scan

Each participant underwent an MRI scan in the supine position using a dual-echo Dixon fat and water sequence on a 3-T MRI scanner (MR750w, GE Healthcare, Chicago, USA). A detailed description of the protocol has been reported previously (Borga et al. 2015; West et al. 2016). Briefly seven overlapping image stacks were acquired from the neck to knee with stacks covering the abdomen (stacks 2 to 5) acquired during breath-hold. Additional abdominal slices were acquired with the IDEAL-IQ sequence to assess proton density fat fraction in the liver. Scans were analysed to quantify visceral adipose tissue, abdominal subcutaneous adipose tissue and liver fat fraction using the AMRA Profiler (AMRA Medical AB, Linköping, Sweden) (Borga et al. 2015; West et al. 2016).

Visit 3: Resting metabolic rate and test meal

All premenopausal female participants completed the main trial during the follicular phase of the menstrual cycle (days 6-12) to avoid potential hormonal influences on appetite parameters. Participants were asked to refrain from caffeine, alcohol, and strenuous exercise during the 24 h before the main trial. A standardised evening meal (3297 kJ, 40% fat, 39% carbohydrate, 21% protein) was consumed the evening before the main trial and only plain water was permitted after the meal until participants arrived at the laboratory the next day.

Participants reported to the laboratory at 08:00 after fasting overnight for 12 h. A cannula (Venflon; Becton Dickinson, Helsingborg, Sweden) was inserted into an antecubital vein for venous blood sampling, and participants rested for 60 min to eliminate any stress effects in response to the cannula (Chandarana et al. 2009). During this time, resting metabolic rate was measured using an open circuit indirect calorimetry system (GEM Nutrition Ltd., Cheshire, England). Participants were asked to lie in a comfortable supine position and were instructed not to talk or sleep, and to move as little as possible during the measurement. The clear hood canopy was placed over the head area, and plastic sheeting attached to the hood was placed around the body to form a seal between the air inside and outside the hood. Oxygen uptake, carbon dioxide production, respiratory exchange ratio and energy expenditure were determined at 30 s intervals over a 30 min period. The first 10 min of data was discarded to account for any initial short-term respiratory artefact.

A fasting venous blood sample and rating of perceived appetite were taken 60 min after the insertion of the cannula. Participants then consumed a standardised breakfast within 15 min marking the start of the postprandial assessment period (09:00; 0 h). Breakfast consisted of a ham and cheese sandwich, milkshake and chocolate biscuit which provided 4435 kJ of energy (41% carbohydrate, 18% protein, 41% fat). Subsequent venous blood samples and ratings of perceived appetite were taken at 0.5, 1 and 2 h after the start of the breakfast whilst the participants rested in a semi-supine position.

Appetite perceptions

Appetite perceptions (hunger, satisfaction, fullness, prospective food consumption) were assessed using 100 mm visual analogue scales (Flint et al. 2000). An overall appetite rating was calculated as the mean value of the four appetite ratings once satisfaction and fullness were reverse-scored (Stubbs et al. 2000).

Blood sampling and biochemical analysis

Venous blood samples were collected into pre-chilled EDTA monovettes (Sarstedt, Leicester, UK) for the determination of plasma acylated ghrelin, total PYY, leptin, insulin and glucose concentrations. Monovettes for acylated ghrelin also contained *p*-hydroxymercuribenzoic acid to prevent the degradation of acylated ghrelin by protease and were centrifuged at 2,383 *g* for 10 min at 4°C (Burkard, Hertfordhire, UK). The plasma supernatant was aliquoted into a storage tube and 100 μL of 1 M hydrochloric acid was added per millilitre of plasma. Samples were re-centrifuged at 2,383 *g* for 5 min at 4°C before being transferred into Eppendorf tubes and stored at -80°C for later analysis. Monovettes for total PYY, leptin, insulin and glucose were centrifuged immediately at 2,383 *g* for 10 min at 4°C prior to storage at -80°C. Haemoglobin concentration and haematocrit were quantified in duplicate at 0 and 2 h to estimate the acute change in plasma volume (Dill and Costill, 1974).

Commercially available enzyme-linked immunosorbent assays were used to determine the concentrations of plasma acylated ghrelin (Bertin Bioreagent, Montigney le Bretonneux, France), total PYY (Millipore, Billerica, MA, USA), leptin (R&D Systems, Minneapolis, MN, USA) and insulin (Mercodia, Uppsala, Sweden). Plasma glucose concentrations were determined by enzymatic, colorimetric methods using a benchtop analyser (Pentra 400, HORIBA Medical, Montpellier, France). The within-batch coefficient of variation for acylated ghrelin, total PYY, leptin, insulin and glucose concentrations were 4.3%, 5.1%, 8.3%, 4.7%, 0.4%, respectively.

An additional fasting venous blood sample was collected into a 2.7-mL EDTA monovette (Sarstedt, Leicester, UK) and the whole blood sample was stored at 4°C to undergo DNA extraction and genotyping. Genomic DNA was extracted from the whole blood samples using the QIAamp DNA Mini kit (QIAGEN, Hilden, Germany). The samples were genotyped for the rs9939609 allele within the FTO gene using the Applied Biosystems TaqMan® (Roche Molecular Systems, Pleasanton, California, USA) genotyping assay and real-time polymerase chain reaction system. Participants were assigned to one of three groups according to their genotype: homozygous major allele, TT (36%; males n = 23, females n = 17); heterozygous allele, AT (45%; males n = 22, females n = 29); or homozygous minor allele, AA (19%; males n = 11, females n = 10). Genotype frequency of FTO rs9939609 was assessed using a goodness-of-fit chi-square test and did not deviate from Hardy-Weinberg equilibrium (χ^2 = 0.435, P = 0.509).

Habitual physical activity and sedentary time

Participants wore an ActiGraph GT3X+ accelerometer (ActiGraph, Pensacola, USA) on an elasticated belt on the waist above the mid-line of the thigh on their non-dominant side of the body. The device was initialised at a frequency of 100HZ and downloaded using ActiLife software v6.11.8 and firmware version 2.0.0. ActiGraph data were downloaded in 60-seconds epochs and physical activity was classified as low, light and moderate-to-vigorous. Participants also wore an activPAL3 accelerometer (PAL Technologies Ltd., Glasgow, UK), attached directly to the skin on the midline of the anterior aspect of the thigh in line with the ActiGraph GT3X+ accelerometer. The activPAL3 determines posture using information derived from accelerations of the thigh, including the gravitational component, using a triaxial accelerometer (Atkin et al. 2012). The activPAL3 is a valid measure of time spent sitting/lying, standing, and walking in adults (Kozey-Keadle et al. 2011). ActivPAL3 sitting time data were retrieved and clustered into 60-seconds epochs using a customized spreadsheet. Participants were advised to wear both devices concurrently and continuously over a 7-day period. Non-wear time and sleep time were removed from the analysis and moderate-to-vigorous physical activity (MVPA) and sitting time data were averaged over the seven-day period.

Statistical analyses

We estimated the effect size detection sensitivity given our sample size using NQuery (version 3, Statistical Solutions, Cork, Ireland). For a total sample size of 110 and three study groups, we

estimated that a "medium" (Cohen, 1998) Eta^2 value of 0.18 would be detected in a univariable model as statistically significant ($P < 0.050$) with power of 90%.

Postprandial overall appetite and plasma concentrations of acylated ghrelin, total PYY, insulin and glucose are presented relative to baseline values (delta) to minimise the potential influence of day-to-day biological variability (Deighton et al. 2013, 2014). Total area under the curve (AUC) values were calculated using the trapezoidal method. Correction of blood parameter concentrations for acute changes in plasma volume had a negligible influence on our findings and, therefore, the unadjusted plasma concentrations are displayed for simplicity.

Multivariable general linear models were used to quantify the mean differences (and 95% confidence intervals) between FTO rs9939609 genotype groups for each fasting and postprandial appetite outcome. The eta-squared statistic (with associated 90% confidence interval) was also estimated for each model and each outcome (Kline, 2004; Steiger, 2004). This statistic is interpreted in a similar way as the coefficient of determination, where 100 x eta-squared gives the explained variance attributable to the FTO groups. A 90% rather than a 95% confidence interval is reported because the eta-squared statistic can only be positive in sign. The model residuals of the appetite outcome variables were explored for parity to a Gaussian distribution using histograms. The model residuals for fasting acylated ghrelin and insulin concentrations were observed to show a positively skewed distribution so these data were logarithmically-transformed prior to analysis (Bland and Altman, 1996). Three models were used for each of the fasting and postprandial appetite outcomes, as follows:

1. Model I: Univariable models with FTO rs9939609 genotype as single fixed effect;
2. Model II: A multivariable model based on the selection of matched covariates studied by Karra et al. (2013), i.e., age, fat mass and visceral adipose tissue. FTO rs9939609 genotype was entered as a fixed effect and sex, age, fat mass and visceral adipose tissue were entered as covariates;
3. Model III: A multivariable model, where FTO rs9939609 genotype was entered as a fixed effect and sex, age, BMI, $V\dot{O}_2$ peak, resting metabolic rate, visceral adipose tissue, abdominal subcutaneous adipose tissue, liver fat, sitting time and MVPA were entered as covariates. Rather than the now discouraged use of stepwise selection procedures, these covariates were included based on their hypothesised influence on the outcome variables, while considering the potential that some predictors were mathematically coupled (Flom and Cassell, 2007; Whittingham et al. 2006). For

example, total fat mass was excluded from this model because multiple specific adiposity parameters were considered.

The covariates in models II and III were each standardised prior to analysis by dividing each datum by twice the respective SD (Gelman and Pardoe, 2007). In sensitivity analyses, model III was also run with (i) waist circumference replacing BMI; (ii) percentage body fat replacing BMI; and (iii) with a sex-by-genotype interaction term.

Univariable general linear models with FTO rs9939609 genotype as a single fixed effect were used to quantify differences between genotype groups for body mass, BMI and fat mass. Between-sex differences in participant characteristics and appetite-related outcomes in the fasting and postprandial states were assessed using univariable general linear models with sex as a single fixed effect. Sex-specific univariable Pearson's correlation coefficients were quantified between appetite-related outcomes and individual characteristics, and between appetite-related blood parameters and perceived appetite.

95% confidence intervals (95% CI) were quantified for correlation coefficients. P-values are expressed in exact terms apart from very low values, which are expressed as $P < 0.001$. A threshold of statistical significance was accepted as $P < 0.050$, although we deemed a P value of < 0.005 as a stronger indication of potentially more reproducible results in line with recent advice (Benjamin et al. 2017). All statistical analyses were performed in SPSS (v.23, IBM Corporation, New York, USA).

RESULTS

Missing data

Due to technical issues with the equipment, resting metabolic rate is presented for 107 participants (53 males), sitting time for 96 participants (47 males) and MVPA for 100 participants (49 males). Eleven participants were unable to undertake the MRI scan for safety reasons and, therefore, visceral adipose tissue and abdominal subcutaneous adipose tissue are presented for 101 participants (50 males). Liver fat could not be quantified from some images due to motion artefacts and, therefore, data is presented for 97 participants (48 males).

Participant characteristics and appetite-related outcomes

Participant characteristics, perceived appetite and appetite-related blood parameters in the fasting and postprandial states are presented in Table 1. Postprandial delta values for acylated

ghrelin, total PYY, insulin and glucose concentrations and perceived overall appetite are presented in Figure 1.

Table 1. Participant characteristics and appetite outcomes in the fasting and postprandial states.

	All (n = 112)	Range (min to max)	Men (n = 56)	Women (n = 56)	*P*	Mean difference 95% CI
Age (years)	34 (9)	18 to 50	35.3 (9.7)	33.5 (9.1)	0.303	-5.4 to 1.7
Stature (cm)	171.0 (9.2)	149.1 to 200.4	178.5 (6.6)	165.3 (6.2)	**< 0.001**	-15.6 to -10.8
Body mass (kg)	74.9 (14.7)	48.5 to 140.4	83.3 (12.9)	66.5 (11.1)	**< 0.001**	-21.2 to -12.2
Body mass index ($kg \cdot m^{-2}$)	25.2 (3.9)	18.4 to 40.3	26.1 (3.7)	24.4 (4.0)	**0.016**	-3.2 to -0.3
Waist circumference (cm)	82.7 (10.8)	62.4 to 125.0	88.4 (9.8)	77.0 (8.7)	**< 0.001**	-14.9 to -8.0
Fat mass (kg)	16.9 (8.4)	3.5 to 47.8	15.5 (9.1)	18.2 (7.4)	0.078	-0.3 to 5.9
Fat free mass (kg)	58.1 (12.2)	36.8 to 92.6	67.8 (8.8)	48.3 (5.5)	**< 0.001**	-22.2 to -16.8
V□O_2 peak ($mL \cdot kg \cdot min^{-1}$)	44.0 (9.3)	21.0 to 81.0	49.0 (9.3)	39.0 (6.1)	**< 0.001**	-13.0 to -7.1
Resting metabolic rate (kcal)*	1617 (322)	889 to 2567	1808 (290)	1430 (232)	**< 0.001**	-478 to -277
Visceral adipose tissue (L)*	1.70 (1.26)	0.11 to 6.22	2.27 (1.41)	1.14 (0.75)	**< 0.001**	-1.58 to -0.69
Abdominal subcutaneous adipose tissue (L)*	5.39 (3.02)	1.45 to 16.86	4.49 (2.39)	6.27 (3.33)	**0.003**	0.64 to 2.93
Liver fat (%)*	2.12 (1.81)	0.46 to 10.45	2.62 (2.19)	1.63 (1.16)	**0.006**	-1.69 to -0.28
Sitting time ($min \cdot day^{-1}$)*	509 (85)	256 to 737	513 (73)	504 (95)	0.630	-43 to 26
MVPA ($min \cdot day^{-1}$)*	55 (31)	11 to 163	57 (30)	54 (33)	0.706	-15 to 10
Fasting leptin ($ng \cdot mL^{-1}$)	8.62 (8.63)	1.34 to 43.85	4.07 (3.08)	13.16 (9.95)	**< 0.001**	6.33 to 11.84
Fasting acylated ghrelin ($pg \cdot mL^{-1}$)	173.6 (491.8)	12.0 to 4410.6	103.3 (108.8)	243.8 (682.9)	0.131	-42.6 to 323.6
Fasting total PYY ($pg \cdot mL^{-1}$)	117.5 (50.5)	13.6 to 270.0	121.9 (47.9)	113.0 (53.1)	0.353	-27.8 to 10.0
Fasting insulin ($pmol \cdot L^{-1}$)	23.3 (15.0)	2.9 to 97.1	22.9 (14.3)	23.6 (15.8)	0.825	-5.0 to 6.3
Fasting glucose ($mmol \cdot L^{-1}$)	5.24 (0.43)	4.29 to 6.56	5.37 (0.43)	5.12 (0.39)	**0.001**	-0.41 to -0.10
Fasting overall appetite (mm)	70.8 (15.3)	19 to 95	71.2 (13.4)	70.4 (17.1)	0.787	-6.5 to 5.0
Acylated ghrelin delta AUC (2 h, $pg \cdot mL^{-1}$)	-87.9 (126.6)	-1183.5 to 165.8	- 51.3 (56.3)	- 124.6 (162.6)	**0.002**	-118.9 to -27.8
Total PYY delta AUC (2 h, $pg \cdot mL^{-1}$)	101.6 (61.0)	-26.4 to 340.7	99.0 (62.4)	104.2 (59.9)	0.653	-17.7 to 28.1
Insulin delta AUC (2 h, $pg \cdot mL^{-1}$)	420.6 (236.8)	121.3 to 1485.8	403.9 (256.6)	437.3 (216.3)	0.458	-55.5 to 122.2
Glucose delta AUC (2 h, $pg \cdot mL^{-1}$)	0.77 (1.59)	-2.20 to 5.79	0.54 (1.37)	1.00 (1.77)	0.125	-0.13 to 1.05
Overall appetite delta AUC (2 h, $pg \cdot mL^{-1}$)	-77.4 (34.4)	-150.0 to -14.0	-65.7 (30.9)	-89.1 (34.0)	**< 0.001**	-35.5 to -11.1

Values are mean (SD). *P* values and 95% CI are from univariable general linear models with sex as a single fixed effect.
* n = 107 (53 males) for resting metabolic rate, 96 (47 males) for sitting time, 100 (49 males) for MVPA, 101 (50 males) for visceral adipose tissue and abdominal subcutaneous adipose tissue, and 97 (48 males) for liver fat.
AUC, area under the curve; CI, confidence interval; MVPA, moderate-to-vigorous physical activity, PYY, peptide YY; V□O_2 peak, peak oxygen uptake.



Figure 1. Delta postprandial values for acylated ghrelin (A), total peptide YY (PYY) (B), insulin (C), glucose (D) and overall perceived appetite (E) in 56 males and 56 females. Grey rectangles indicate meal consumed within 15 min. Values are presented as mean (SD). * indicates $P < 0.05$ between males and females.

Univariable and multivariable general linear models

No statistically significant influence of the FTO rs9939609 genotype was identified for body mass ($Eta^2 = 0.027$, $P = 0.234$), BMI ($Eta^2 = 0.003$, $P = 0.688$) or fat mass ($Eta^2 = 0.025$, $P = 0.259$).

Fasting appetite-related outcomes

Separate univariate modelling (model I) did not reveal any statistically significant influence of the FTO rs9939609 genotype on fasting acylated ghrelin, total PYY, insulin, glucose, leptin or overall appetite ($P \geq 0.501$) (Table 2). Similarly, no significant effect of the FTO rs9939609 genotype was detected on fasting appetite-related outcomes in model II ($P \geq 0.098$) or model III ($P \geq 0.453$) (Table 2). All eta-squared values were very low (< 0.05). Replacing BMI with waist circumference, replacing BMI with body fat percentage, and including a sex-by-genotype interaction term in the sensitivity analyses did not result in a significant effect of the FTO rs9939609 genotype on any of the fasting appetite-related outcomes ($P \geq 0.470$, $P \geq 0.437$, $P \geq 0.455$, respectively).

Postprandial appetite-related outcomes

Separate univariate modelling (model I) did not reveal any statistically significant influence of the FTO rs9939609 genotype on delta AUC for acylated ghrelin, total PYY, insulin, glucose, leptin or overall appetite ($P \geq 0.322$) (Table 3). Similarly, no significant effect of the FTO rs9939609 genotype was detected on delta AUC for any of the appetite-related outcomes in model II ($P \geq 0.271$) or model III ($P \geq 0.186$) (Table 3). Again, all eta-squared values were very low (< 0.05). Replacing BMI with waist circumference, replacing BMI with body fat percentage, and including a sex-by-genotype interaction term in the sensitivity analyses did not result in a significant effect of the FTO rs9939609 genotype on any of the postprandial appetite-related outcomes ($P \geq 0.133$, $P \geq 0.102$, $P \geq 0.206$, respectively). A sensitivity analysis was undertaken on all the postprandial outcomes AUC by adding the respective fasting measurement as a covariate to the model. Again, no statistically significant differences between FTO groups could be detected ($P > 0.200$) and mean differences were small.

Table 2. Estimated marginal means from the multivariable general linear models used to quantify the differences between FTO rs9939609 genotype groups in each fasting appetite outcome.

	Model I			Model II			Model III		
	AT (n = 49)	**AA (n = 21)**	**TT (n = 40)**	**AT (n = 45)**	**AA (n = 18)**	**TT (n = 37)**	**AT (n = 34)**	**AA (n = 17)**	**TT (n = 28)**
Fasting acylated ghrelin (log pg·mL^{-1})	4.47 (4.25 to 4.69)	4.59 (4.26 to 4.92)	4.51 (4.27 to 4.75)	4.42 (4.18 to 4.65)	4.57 (4.20 to 4.94)	4.57 (4.30 to 4.83)	4.42 (4.20 to 4.64)	4.56 (4.23 to 4.88)	4.29 (4.03 to 4.54)
	Eta^2 = 0.003 (90% CI: 0.000-0.023), *P* = 0.835			Eta^2 = 0.009 (90% CI: 0.000-0.047), *P* = 0.660			Eta^2 = 0.024 (90% CI: 0.000-0.091), *P* = 0.453		
Fasting total PYY (pg·mL^{-1})	110.3 (96.1 to 124.5)	123.5 (101.8 to 145.2)	120.4 (104.7 to 136.2)	109.2 (94.0 to 124.4)	123.6 (100.2 to 147.0)	122.4 (105.7 to 139.1)	114.3 (97.6 to 130.9)	117.2 (93.3 to 141.0)	114.1 (95.0 to 133.2)
	Eta^2 = 0.013 (90% CI: 0.000-0.055), *P* = 0.501			Eta^2 = 0.018 (90% CI: 0.000-0.069), *P* = 0.434			Eta^2 = 0.001 (90% CI: 0.000-0.014), *P* = 0.977		
Fasting insulin (log pmol·L^{-1})	3.00 (2.83 to 3.16)	2.87 (2.61 to 3.12)	2.97 (2.79 to 3.16)	3.03 (2.88 to 3.19)	2.93 (2.70 to 3.17)	2.96 (2.79 to 3.13)	3.01 (2.81 to 3.20)	2.98 (2.70 to 3.27)	2.95 (2.72 to 3.18)
	Eta^2 = 0.007 (90% CI: 0.000-0.038), *P* = 0.699			Eta^2 = 0.007 (90% CI: 0.000-0.041), *P* = 0.716			Eta^2 = 0.002 (90% CI: 0.000-0.028), *P* = 0.935		
Fasting glucose (mmol·L^{-1})	5.23 (5.11 to 5.36)	5.28 (5.09 to 5.47)	5.22 (5.09 to 5.36)	5.27 (5.15 to 5.38)	5.28 (5.11 to 5.46)	5.14 (5.02 to 5.27)	5.24 (5.10 to 5.38)	5.30 (5.10 to 5.51)	5.16 (5.00 to 5.32)
	Eta^2 = 0.002 (90% CI: 0.000-0.016), *P* = 0.882			Eta^2 = 0.027 (90% CI: 0.000-0.087), *P* = 0.278			Eta^2 = 0.018 (90% CI: 0.000-0.078), *P* = 0.553		
Fasting leptin (ng·mL^{-1})	9.17 (6.70 to 11.65)	8.06 (4.27 to 11.84)	7.95 (5.21 to 10.69)	9.77 (8.15 to 11.39)	6.67 (4.17 to 9.17)	7.93 (6.15 to 9.71)	9.76 (7.91 to 11.62)	8.71 (6.05 to 11.37)	8.72 (6.59 to 10.85)
	Eta^2 = 0.005 (90% CI: 0.000-0.030), *P* = 0.779			Eta^2 = 0.049 (90% CI: 0.000-0.122), *P* = 0.098			Eta^2 = 0.010 (90% CI: 0.000-0.057), *P* = 0.713		
Fasting overall appetite (mm)	70.0 (65.7 to 74.4)	69.6 (63.0 to 76.2)	72.2 (67.4 to 77.0)	67.6 (63.0 to 72.3)	70.2 (63.0 to 77.4)	72.4 (67.3 to 77.6)	66.8 (60.9 to 72.7)	68.9 (60.4 to 77.3)	69.3 (62.5 to 76.0)
	Eta^2 = 0.005 (90% CI: 0.000-0.033), *P* = 0.748			Eta^2 = 0.019 (90% CI: 0.000-0.072), *P* = 0.402			Eta^2 = 0.005 (90% CI: 0.000-0.034), *P* = 0.850		

Model I: Univariable model with FTO rs9939609 genotype as single fixed effect. Model II: Multivariable model with FTO rs9939609 genotype as a fixed effect and sex, age, fat mass and visceral adipose tissue as covariates. Model III: Multivariable model with FTO rs9939609 genotype as a fixed effect and sex, age, body mass index, peak oxygen uptake, resting metabolic rate, visceral adipose tissue, abdominal subcutaneous adipose tissue, liver fat, sitting time and moderate-to-vigorous physical activity as covariates.

Values are mean (95% confidence interval (CI)). Eta^2, 90% CI and *P*-values are from the fixed effect of the FTO rs9939609 genotype group.

Table 3. Estimated marginal means from the multivariable general linear models used to quantify the differences between FTO rs9939609 genotype groups in each postprandial appetite outcome.

	Model I			Model II			Model III		
	AT (n = 49)	**AA (n = 21)**	**TT (n = 40)**	**AT (n = 45)**	**AA (n = 18)**	**TT (n = 37)**	**AT (n = 34)**	**AA (n = 17)**	**TT (n = 28)**
Acylated ghrelin delta AUC (2 h pg·mL^{-1})	-76.0 (-110.8 to -41.2)	-86.3 (-139.5 to -33.1)	-96.3 (-134.9 to -57.8)	-69.5 (-107.1 to -32.0)	-93.1 (-151.1 to -35.0)	-103.2 (-144.5 to -61.8)	-87.4 (-106.9 to -67.9)	-87.0 (-114.9 to -59.0)	-67.8 (-90.2 to -45.4)
	Eta^2 = 0.006 (90% CI: 0.000-0.034), *P* = 0.740			Eta^2 = 0.015 (90% CI: 0.000-0.063), *P* = 0.494			Eta^2 = 0.026 (90% CI: 0.000-0.097), *P* = 0.414		
Total PYY delta AUC (2 h pg·mL^{-1})	101.1 (84.2 to 118.1)	89.7 (63.8 to 115.6)	113.4 (94.7 to 132.2)	98.5 (80.2 to 116.8)	86.5 (58.2 to 114.8)	113.7 (93.5 to 133.8)	103.5 (81.2 to 125.8)	80.4 (48.4 to 112.4)	120.1 (94.4 to 145.7)
	Eta^2 = 0.021 (90% CI: 0.000-0.072), *P* = 0.322			Eta^2 = 0.028 (90% CI: 0.000-0.088), *P* = 0.271			Eta^2 = 0.050 (90% CI: 0.000-0.137), *P* = 0.186		
Insulin delta AUC (2 h pmol·L^{-1})	411 (345 to 476)	404 (303 to 503)	432 (359 to 504)	409 (342 to 477)	415 (311 to 519)	430 (356 to 504)	411 (330 to 492)	429 (313 to 545)	463 (370 to 556)
	Eta^2 = 0.002 (90% CI: 0.000-0.017), *P* = 0.875			Eta^2 = 0.002 (90% CI: 0.000-0.022), *P* = 0.921			Eta^2 = 0.010 (90% CI: 0.000-0.055), *P* = 0.728		
Glucose delta AUC (2 h mmol·L^{-1})	0.66 (0.21 to 1.12)	0.60 (-0.10 to 1.30)	1.01 (0.51 to 1.52)	0.60 (0.19 to 1.02)	0.54 (-0.09 to 1.18)	0.79 (0.34 to 1.25)	0.68 (0.19 to 1.17)	0.44 (-0.26 to 1.14)	0.88 (0.32 to 1.44)
	Eta^2 = 0.012 (90% CI: 0.000-0.054), *P* = 0.511			Eta^2 = 0.006 (90% CI: 0.000-0.036), *P* = 0.766			Eta^2 = 0.013 (90% CI: 0.000-0.066), *P* = 0.642		
Overall appetite delta AUC (2 h mm)	-79.3 (-89.1 to -69.5)	-72.4 (-87.4 to -57.5)	-79.2 (-90.1 to -68.4)	-75.3 (-85.2 to -65.4)	-73.6 (-88.8 to -58.3)	-82.1 (-93.0 to -71.2)	-73.4 (-85.4 to -61.4)	-75.6 (-92.7 to -58.4)	-75.6 (-89.3 to -61.8)
	Eta^2 = 0.006 (90% CI: 0.000-0.036), *P* = 0.718			Eta^2 = 0.012 (90% CI: 0.000-0.056), *P* = 0.568			Eta^2 = 0.001 (90% CI: 0.000-0.021), *P* = 0.965		

Model I: Univariable model with FTO rs9939609 genotype as single fixed effect. Model II: Multivariable model with FTO rs9939609 genotype as a fixed effect and sex, age, fat mass and visceral adipose tissue as covariates. Model III: Multivariable model with FTO rs9939609 genotype as a fixed effect and sex, age, body mass index, peak oxygen uptake, resting metabolic rate, visceral adipose tissue, abdominal subcutaneous adipose tissue, liver fat, sitting time and moderate-to-vigorous physical activity as covariates.

Values are mean (95% confidence interval (CI)). Eta^2, 90% CI and *P*-values are from the fixed effect of the FTO rs9939609 genotype group.

Sex-specific Pearson's correlation coefficients

Appetite-related outcomes and individual characteristics

No significant correlations were observed between fasting acylated ghrelin and age, BMI, fat mass, V□O_2 peak, resting metabolic rate, visceral fat, abdominal subcutaneous adipose tissue, liver fat, average sitting or average MVPA in men (r = -0.18 to 0.07, P ≥ 0.185) or women (r = -0.19 to 0.06, P ≥ 0.175). Similarly, no significant correlations were observed between fasting total PYY and any of the individual characteristics in men (r = -0.13 to 0.14, P ≥ 0.330) or women (r = -0.14 to 0.10, P ≥ 0.323). Pearson's correlation coefficients between individual characteristics and fasting insulin, glucose and leptin are presented in Table 4. In summary, fasting insulin was positively correlated with general and abdominal adiposity parameters in both sexes and with liver fat in men (r = 0.32 to 0.53, P ≤ 0.010). Fasting insulin was negatively correlated with V□O_2 peak in both sexes and with MVPA in men (r = -0.35 to -0.47, P ≤ 0.004). Fasting glucose was positively correlated with total and abdominal adiposity parameters in both sexes, with age and liver fat in men, and with resting metabolic rate in women (r = 0.28 to 0.44, P ≤ 0.017). Fasting glucose was negatively correlated with V□O_2 peak in both sexes (r = -0.29 to -0.28, P ≤ 0.020). Fasting leptin was positively correlated with general and abdominal adiposity parameters in both sexes, and with age and liver fat in men (r = 0.24 to 0.83, P ≤ 0.040). Fasting leptin was negatively correlated with V□O_2 peak in both sexes and with MVPA in men (r = -0.35 to -0.64, P ≤ 0.006). In men, fasting overall appetite was negatively associated with fat mass (r = -0.31, P = 0.022, 95% CI = -0.53 to -0.05) and abdominal subcutaneous adipose tissue (r = -0.30, P = 0.032, 95% CI = -0.53 to -0.02). No significant correlations between fasting overall appetite and individual characteristics were observed in women (r = -0.12 to 0.09, P ≥ 0.391).

Delta AUC for acylated ghrelin was positively associated with sitting time (r = 0.29, *P* = 0.048, 95% CI = 0.00 to 0.53) and negatively associated with age (r = -0.32, *P* = 0.017, 95% CI = -0.54 to -0.06) in men. Insulin AUC was positively associated with visceral adipose tissue in men (r = 0.38, *P* = 0.007, 95% CI = 0.11 to 0.59) and women (r = 0.32, *P* = 0.021, 95% CI = 0.05 to 0.55), and with fat mass (r = 0.39, *P* = 0.003, 95% CI = 0.14 to 0.59), abdominal subcutaneous adipose tissue (r = 0.31, *P* = 0.026, 95% CI = 0.03 to 0.54) and liver fat (r = 0.47, *P* = 0.001, 95% CI = 0.21 to 0.66) in men. Insulin AUC was negatively associated with V□O_2 peak (r = -0.44, *P* = 0.001, 95% CI = -0.63 to -0.20) and MVPA (r = -0.38, *P* = 0.007, 95% CI = -0.60 to -0.11) in

men. None of the correlations between AUC for total PYY, glucose and overall appetite and individual characteristics were statistically significant ($r = -0.23$ to 0.24, $P \geq 0.061$).

Table 4. Sex-specific Pearson's correlation coefficients between fasting appetite-related blood markers and individual characteristics.

	Fasting insulin ($pmol \cdot L^{-1}$)	Fasting glucose ($mmol \cdot L^{-1}$)	Fasting leptin ($ng \cdot mL^{-1}$)
Age (years)	Men: r = -0.01, *P* = 0.457, 95% CI = -0.27 to 0.25 Women: r = -0.16, *P* = 0.123, 95% CI = -0.40 to 0.11	**Men: r = 0.34, *P* = 0.005, 95% CI = 0.08 to 0.55** Women: r = 0.08, *P* = 0.270, 95% CI = -0.19 to 0.33	**Men: r = 0.24, *P* = 0.040, 95% CI = -0.02 to 0.47** Women: r = -0.07, *P* = 0.298, 95% CI = -0.33 to 0.20
Body mass index ($kg \cdot m^{-2}$)	**Men: r = 0.39, P = 0.003, 95% CI = 0.14 to 0.59** **Women: r = 0.53, P < 0.001, 95% CI = 0.31 to 0.69**	**Men: r = 0.33, *P* = 0.013, 95% CI = 0.07 to 0.54** **Women: r = 0.35, *P* = 0.004, 95% CI = 0.10 to 0.56**	**Men: r = 0.62, *P* < 0.001, 95% CI = 0.43 to 0.76** **Women: r = 0.77, *P* < 0.001, 95% CI = 0.64 to 0.86**
Fat mass (kg)	**Men: r = 0.49, *P* < 0.001, 95% CI = 0.26 to 0.67** **Women: r = 0.32, *P* = 0.008, 95% CI = 0.06 to 0.54**	**Men: r = 0.44, *P* < 0.001, 95% CI = 0.20 to 0.63** **Women: r = 0.28, *P* = 0.017, 95% CI = 0.02 to 0.50**	**Men: r = 0.83, *P* < 0.001, 95% CI = 0.73 to 0.90** **Women: r = 0.75, *P* < 0.001, 95% CI = 0.61 to 0.85**
V□O_2 peak ($mL \cdot kg \cdot min^{-1}$)	**Men: r = -0.47, *P* < 0.001, 95% CI = -0.65 to -0.24** **Women: r = -0.35, *P* = 0.004, 95% CI = -0.56 to -0.10**	**Men: r = -0.29, *P* = 0.015, 95% CI = -0.51 to -0.03** **Women: r = -0.28, *P* = 0.020, 95% CI = -0.50 to -0.02**	**Men: r = -0.64, *P* < 0.001, 95% CI = -0.77 to -0.45** **Women: r = -0.58, *P* < 0.001, 95% CI = -0.73 to -0.37**
Resting metabolic rate (kcal)	Men: r = -0.04, *P* = 0.381, 95% CI = -0.31 to 0.23 Women: r = 0.03, *P* = 0.402, 95% CI = -0.24 to 0.29	Men: r = -0.12, *P* = 0.205, 95% CI = -0.38 to 0.15 **Women: r = 0.35, *P* = 0.005, 95% CI = 0.09 to 0.56**	Men: r = 0.05, *P* = 0.369, 95% CI = -0.22 to 0.32 Women: r = 0.05, *P* = 0.359, 95% CI = -0.22 to 0.31
Visceral adipose tissue (L)	**Men: r = 0.41, *P* = 0.002, 95% CI = 0.15 to 0.62** **Women: r = 0.33, *P* = 0.010, 95% CI = 0.06 to 0.55**	**Men: r = 0.42, *P* = 0.001, 95% CI = 0.15 to 0.63** **Women: r = 0.36, *P* = 0.005, 95% CI = 0.09 to 0.58**	**Men: r = 0.65, *P* < 0.001, 95% CI = 0.45 to 0.79** **Women: r = 0.62, *P* < 0.001, 95% CI = 0.42 to 0.76**
Abdominal subcutaneous adipose tissue (L)	**Men: r = 0.43, *P* = 0.002, 95% CI = 0.17 to 0.63** **Women: r = 0.44, *P* = 0.001, 95% CI = 0.19 to 0.64**	**Men: r = 0.39, *P* = 0.005, 95% CI = 0.13 to 0.60** **Women: r = 0.34, *P* = 0.013, 95% CI = 0.07 to 0.56**	**Men: r = 0.79, P < 0.001, 95% CI = 0.66 to 0.87** **Women: r = 0.79, P < 0.001, 95% CI = 0.66 to 0.87**
Liver fat (%)	**Men: r = 0.49, *P* < 0.001, 95% CI = 0.24 to 0.68** Women: r = 0.06, *P* = 0.338, 95% CI = -0.22 to 0.33	**Men: r = 0.33, *P* = 0.010, 95% CI = 0.05 to 0.56** Women: r = 0.07, *P* = 0.305, 95% CI = -0.21 to 0.34	**Men: r = 0.44, *P* = 0.001, 95% CI = 0.18 to 0.64** Women: r = 0.18, *P* = 0.112, 95% CI = -0.11 to 0.44
Average sitting time ($min \cdot day^{-1}$)	Men: r = -0.06, *P* = 0.340, 95% CI = -0.34 to 0.23 Women: r = 0.12, *P* = 0.196, 95% CI = -0.17 to 0.39	Men: r = -0.12, *P* = 0.210, 95% CI = -0.39 to 0.17 Women: r = 0.13, *P* = 0.190, 95% CI = -0.16 to 0.40	Men: r = -0.12, *P* = 0.207, 95% CI = -0.39 to 0.17 Women: r = 0.05, *P* = 0.353, 95% CI = -0.23 to 0.33
Average MVPA time ($min \cdot day^{-1}$)	**Men: r = -0.44, *P* = 0.001, 95% CI = -0.64 to -0.18** Women: r = -0.01, *P* = 0.493, 95% CI = -0.28 to 0.27	Men: r = -0.03, *P* = 0.420, 95% CI = -0.31 to 0.25 Women: r = 0.09, *P* = 0.274, 95% CI = -0.19 to 0.36	**Men: r = -0.35, *P* = 0.006, 95% CI = -0.57 to -0.08** Women: r = -0.10, *P* = 0.241, 95% CI = -0.36 to 0.18

AUC, area under the curve; FTO, fat mass and obesity associated gene; MVPA, moderate-to-vigorous physical activity, PYY, peptide YY; V□O_2 peak, peak oxygen uptake.

Perceived appetite and appetite-related blood parameters

Fasting overall appetite was negatively associated with fasting insulin (r = -0.32, P = 0.015, 95% CI = -0.54 to -0.06) and fasting leptin (r = -0.35, P = 0.008, 95% CI = -0.56 to -0.10) in men. Delta AUC for overall appetite was positively associated with insulin AUC (r = 0.35, P = 0.009, 95% CI = 0.10 to 0.56) in women. No other significant correlations between overall appetite and appetite-related blood parameters were evident in the fasted or postprandial state (r = -0.20 to 0.26, $P \geq 0.052$).

DISCUSSION

The primary finding of this study is that very little influence of the FTO rs9939609 genotype was identified for fasting and postprandial perceived appetite and appetite-related blood outcomes in healthy men and women. Explained variance for FTO group on all outcomes was small (< 5%) according to the thresholds suggested by Cohen (1998). Even the upper 90% confidence limits of the explained variance were low for each outcome (< 15%). In the context of precision medicine, we maintain that explained variance would need to be much larger than our observed values for the FTO rs9939609 gene to be a useful predictor of appetite-related outcomes. We also found that fasting and postprandial acylated ghrelin and total PYY were not associated with general or abdominal adiposity, while leptin, glucose and insulin concentrations were consistently associated with adiposity variables. Our study is the first to employ an integrative approach to investigate associations between a variety of genetic, physiological and lifestyle characteristics with appetite-related outcomes. Previous research has provided limited evidence on the influence of specific individual characteristics on appetite-related blood parameters and appetite perceptions.

The FTO gene represents the most extensively-studied gene that has been associated with a higher risk of obesity (Frayling et al. 2007), yet evidence on the physiological mechanisms involved is limited. The study undertaken by Karra et al. (2013) supported the hypothesis that satiety control differs between FTO rs9939609 genotype groups. Specifically, the group with higher obesity risk (AA) presented attenuated suppression of acylated ghrelin and perceived hunger after consumption of a meal, which can naturally lead to higher energy intake and, consequently, higher body mass (Karra et al. 2013). However, our results do not support this hypothesis as we found very little influence of genotype group on acylated ghrelin concentrations or perceived appetite ratings. Differences between study samples can possibly explain

discrepancies between findings, as Karra et al. (2013) recruited healthy young lean males, while our sample was composed of a heterogeneous group of males and females. Additionally, Karra et al. (2013) selectively sampled their participants in order to match groups for certain variables, whereas we adopted a multivariate-adjusted approach to our data analysis. Interestingly, recent studies have reported lower postprandial total ghrelin concentrations in AA compared to AT and TT individuals (Magno et al. 2018; Melhorn et al. 2018), and postprandial hunger ratings were either similar between genotype groups (Melhorn et al. 2018) or were lower in AA individuals (Magno et al. 2018). These findings were observed despite the AA individuals exhibiting higher energy intake during an *ad libitum* buffet (Melhorn et al. 2018). Of note, the active part of ghrelin (acylated ghrelin) only represents approximately 5 to 10% of total ghrelin (Hosoda et al, 2000; Yoshimoto et al. 2002) and, therefore, the assessment of total ghrelin in these studies could potentially explain the variability in findings.

Our research group has recently conducted a replicated crossover study to examine individual appetite responses to meal intake in healthy men recruited according to their FTO rs9939609 genotype (AA or TT) (Goltz et al. 2019). The findings from this study highlighted the existence of interindividual variability in perceived appetite and acylated ghrelin, total PYY, insulin and glucose responses to a standardised meal over and above any measurement errors and/or natural variance of the outcomes. However, the magnitude of postprandial appetite parameter responses after meal intake was not influenced by the FTO rs9939609 gene (Goltz et al. 2019). In line with our findings, previous studies have reported no differences between FTO rs9939609 genotype groups for fasting glucose and insulin (Speakman et al. 2008), fasting leptin (Speakman et al. 2008; Karra et al. 2013; Melhorn et al. 2018), fasting and postprandial PYY_{3-36} (Karra et al. 2013) and fasting and postprandial GLP-1 (Melhorn et al. 2018). Beyond the subjective appetite and appetite-related blood outcomes assessed in this study, AA and TT individuals have been shown to exhibit divergent neural responsiveness to food cues within homeostatic and reward brain regions in both fasted and postprandial states (Karra et al. 2013). Specifically, AA individuals rated high-energy food images as more appealing than TT individuals, and positive associations between circulating acylated ghrelin and central neural system responsiveness to food cues were observed only in TT individuals (Karra et al. 2013). Moreover, recent evidence suggests that AA individuals show higher total food cravings, compared to TT individuals, which correlated with BMI (Dang et al. 2018). Additional studies are needed to elucidate the precise role that FTO rs9939609 plays in moderating appetite control and energy intake which include both central and peripheral factors implicated in appetite regulation.

Although evidence to date suggests a negligible impact of FTO rs9939609 genotype on energy expenditure, higher levels of physical activity seem to exert a protective effect on the obesity risk associated with FTO (Sonestedt et al. 2009; Speakman, 2015). On the contrary, diets with higher fat content can exacerbate the susceptibility to obesity linked to the FTO rs9939609 high-risk genotype (Sonestedt et al. 2009; Speakman, 2015). Our study included objectively assessed sitting time, MVPA and cardiorespiratory fitness as covariates in the statistical analyses. However, only 20% of our participants accumulated, on average, less than 30 min of MVPA per day, indicating that most participants in our sample had relatively high levels of physical activity. Therefore, we cannot rule out the possibility of this hindering our ability to detect differences in appetite-related outcomes between the genotype groups (Speakman et al. 2008). Our study did not include any assessment of habitual dietary intake and, therefore, fat intake was not taken into consideration in our analyses. Nevertheless, it is well known that the currently available dietary intake assessment tools do not provide reliable data, and this currently represents a major challenge for those involved in nutrition-related research, clinical practice or policy development (Dhurandhar et al. 2015; Archer et al. 2018).

In contrast to previous studies (Alajmi et al. 2016; Douglas et al. 2017), we did not observe a statistically significant difference in fasting concentrations of acylated ghrelin between men and women. The reason for this disparity is unclear but it is worth noting that two female participants were identified as clear outliers within our sample, with fasting acylated ghrelin concentrations of 2,899 and 4,411 $pg \cdot mL^{-1}$. These extremely high concentrations of acylated ghrelin were observed consistently in all four samples collected for each participant, indicating these values represented physiological characteristics of these two individuals rather than merely one-off measurement errors. Further studies are needed to investigate potential causes and consequences of such extreme concentrations of acylated ghrelin, and care should be taken when interpreting group mean results, as group means can be greatly impacted by such outliers. Nevertheless, exclusion of the outliers did not influence any of the statistical models in this study and, therefore, data are presented with the outliers included. Higher concentrations of fasting glucose were observed in men than women in the current study, which may be indicative of a greater degree of insulin resistance resulting from the higher visceral adipose tissue and liver fat levels observed in men (Marchesini et al, 2001; Ibrahim, 2010). Higher levels of fasting leptin were observed in women, likely because of the higher fat mass values in relation to total body mass in women, compared to men (Marshall et al. 2000; Rosenbaum and Leibel, 2014).

After meal consumption, greater changes in acylated ghrelin and overall appetite were observed in women than men. It should be noted that all participants received an identical standardised meal and, as women had significantly lower body mass and fat free mass, and consequently lower resting metabolic rate, it was expected that the postprandial suppression of appetite would be stronger in women. However, it is interesting to observe that, apart from acylated ghrelin, no other statistically significant differences were observed between men and women in any of the remaining postprandial appetite-related blood parameters. Previous evidence has demonstrated a stronger suppression of acylated ghrelin in women than men after acute exercise and standardised meals (Douglas et al. 2017), but not after the consumption of a standardised liquid meal (Carroll et al. 2007).

Our exploratory analyses did not identify any statistically significant or meaningful association between adiposity parameters and fasting or postprandial concentrations of acylated ghrelin and total PYY. This is in contrast with findings from previous studies which demonstrated a lower postprandial suppression of total and acylated ghrelin (Le Roux et al. 2005; Carrol et al. 2007) and a blunted postprandial elevation in PYY (Le Roux et al. 2006) in individuals with obesity. However, as expected, fasting insulin, glucose and leptin and postprandial insulin were all positively associated with general and visceral adiposity, demonstrated by moderate to very large correlation coefficients, which is consistent with the well-established role of leptin in signalling adiposity levels (Rosenbaum and Leibel, 2014) and the impact of adiposity on insulin resistance (Ibrahim, 2010). Additionally, fat free mass, which represents the largest determinant of resting metabolic rate, has been identified as a primary determinant of appetite and energy intake (Blundell et al. 2015b). However, our findings did not reveal any significant associations of appetite-related hormones or perceived appetite with resting metabolic rate.

While acute bouts of exercise have been shown consistently to transiently suppress appetite (King et al. 2017), chronic exercise and high levels of physical activity have been suggested to increase the overall drive to eat and, concomitantly, to increase the satiating effect of a standardised meal (King et al. 2009; Beaulieu et al. 2016). We did not identify any significant associations between habitual physical activity levels and fasting or postprandial acylated ghrelin, total PYY, glucose or perceived appetite. However, a negative association was observed between MVPA and fasting leptin and insulin, and postprandial insulin in men. Additionally, negative associations between V□O_2 peak and fasting and postprandial insulin, fasting glucose and fasting leptin were observed. Acute and chronic exercise augments insulin sensitivity by increasing insulin-like growth factor

1, and individuals with higher cardiorespiratory fitness typically show higher insulin sensitivity (Borghouts and Keizer, 2000; Castro et el. 2016). Furthermore, a recent meta-analysis showed that leptin concentrations can be reduced by exercise in individuals who are overweight even in the absence of dietary interventions or major weight loss (BMI reduction of > 2.5%) (Rostás et al. 2017). Postprandial acylated ghrelin was positively associated with sitting time in men, but this correlation was small in magnitude and would not be considered significant if the stricter threshold of $P < 0.005$ was applied in line with recent recommendations (Benjamin et al. 2017).

Perceived fasting overall appetite was negatively associated with total fat mass in men supporting previous evidence suggesting the existence of negative feedback signals originating from fat mass in order to regulate appetite and maintain body weight (Weise et al. 2014; Blundell et al. 2015a). However, no association was observed between postprandial perceived appetite and any adiposity parameter in our study. Interestingly, no statistically significant associations between fasting or postprandial perceived overall appetite and acylated ghrelin or total PYY were identified. Even though circulating concentrations of acylated ghrelin and PYY vary on a meal-to-meal basis, concomitantly with perceived appetite, the magnitude and direction of the changes in hormone concentrations are not always mirrored by changes in perceived appetite (Goltz et al. 2018). In contrast, postprandial overall appetite AUC was positively associated with postprandial insulin AUC in women, which is consistent with previous findings showing that postprandial insulin concentrations are positively associated with postprandial satiety and negatively associated with postprandial hunger (Flint et al. 2007).

The strengths of our study include the use of an integrative approach and objective assessment methods to explore the associations of the FTO rs9939609 genotype with fasting and postprandial appetite-related hormones and perceived appetite, taking into consideration a variety of individual characteristics that have been previously suggested to influence appetite parameters. Furthermore, the recruitment of a highly heterogeneous sample for parameters such as age, adiposity and cardiorespiratory fitness levels adds strength to our analyses. Finally, the careful standardisation of diet and physical activity in the 24 h preceding the laboratory visit, as well as the inclusion of a cannula acclimatisation period, also contributed to the quality of the study outcome measurements obtained. However, it should be highlighted that our study employed an exploratory approach and the cross-sectional design makes it impossible to imply any causation in our results. Our results may have been compromised by the reduced sample size and by the loss of power in some of the statistical models due to missing data. Additionally, it is possible

that a study design where individuals are exposed to an obesigenic food environment, such as an *ad libitum* buffet meal rather than a standardised meal stimulus, may be more appropriate to elucidate the effect of FTO rs9939609 genotype on food choice and eating behaviour. Furthermore, participants were aware of the meal timing so it is possible that the higher preprandial ghrelin concentrations reflected an anticipatory response to impending meal intake (Cummings et al. 2001). Future studies should consider isolating meal provision from time-related cues and/or examining the influence of cephalic phase ghrelin release during meal anticipation on postprandial appetite responses.

In conclusion, the FTO rs9939609 genotype did not have any significant influence on fasting or postprandial perceived appetite or appetite-related blood parameters in healthy men and women. The associations between fasting and postprandial acylated ghrelin, total PYY and general or abdominal adiposity were also small, while fasting leptin, glucose and insulin and postprandial insulin concentrations were consistently and positively associated with adiposity outcomes. Further research is needed to clarify the precise role of the FTO rs9939609 genotype in moderating appetite control and energy intake, including both physiological and psychological factors that influence eating behaviour. Specifically, well-controlled long-term studies are needed to improve understanding of the effect of the FTO rs9939609 genotype on appetite and energy intake during and after interventions targeting weight loss and/or prevention of weight gain. Understanding the complex interaction between genetics and other individual characteristics, physiological appetite parameters and perceived appetite is of crucial importance for planning targeted strategies for weight control.

ACKNOWLEDGEMENTS

This research was funded by the NIHR Leicester Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

REFERENCES

Alajmi N, Deighton K, King JA, Reischak-Oliveira A, Wasse LK, Jones J, et al. Appetite and energy intake responses to acute energy deficits in females versus males. Med Sci Sports Exerc. 2016;48(3):412-20.

Archer E, Lavie CJ, Hill JO. The failure to measure dietary intake engendered a fictional discourse on diet-disease relations. Front Nutr. 2018;5:105.

Atkin AJ, Gorely T, Clemes SA, Yates T, Edwardson C, Brage S, et al. Methods of measurement in epidemiology: sedentary behaviour**.** Int J Epidemiol. 2012;41(5):1460-71.

Atkinson G, Batterham AM. True and false interindividual differences in the physiological response to an intervention. Exp Physiol 2015;100(6):577-88.

Beaulieu K, Hopkins M, Blundell J, Finlayson G. Does habitual physical activity increase the sensitivity of the appetite control system? A systematic review. Sports Med. 2016;46(12):1897-919.

Benjamin DJ, Berger J, Johannesson M, Nosek BA, Wagenmakers E, Berk R, et al. Redefine statistical significance. PsyArXiv (online). 2017. Available at: https://doi.org/10.31234/osf.io/mky9j (Accessed on: January 11, 2019).

Bland JM, Altman DG. Transforming data. BMJ. 1996;23;312(7033):770.

Blundell JE, Finlayson G, Gibbons C, Caudwell P, Hopkins M. The biology of appetite control: Do resting metabolic rate and fat-free mass drive energy intake? Physiol Behav. 2015;152(Pt B):473-8.

Blundell JE, Gibbons C, Caudwell P, Finlayson G, Hopkins M. Appetite control and energy balance: impact of exercise. Obes Rev. 2015;16 Suppl 1:67-76.

Blundell JE, Levin F, King NA, Barkeling B, Gustafsson T, Hellstrom PM, et al. Overconsumption and obesity: peptides and susceptibility to weight gain. Regul Pept. 2008;149(1-3):32-8.

Borg GA. Perceived exertion. A note on ‘‘history’’ and methods. Med Sci Sports. 1973;5(2):90–3.

Borga M, Thomas EL, Romu T, Rosander J, Fitzpatrick J, Dahlqvist Leinhard O, et al. Validation of a fast method for quantification of intra-abdominal and subcutaneous adipose tissue for large-scale human studies. NMR Biomed. 2015;28(12):1747-53.

Borghouts LB, Keizer HA. Exercise and insulin sensitivity: a review. Int J Sports Med. 2000;21(1):1-12.

Carroll JF, Kaiser KA, Franks SF, Deere C, Caffrey JL. Influence of BMI and gender on postprandial hormone responses. Obesity. 2007;15(12):2974-83.

Castro MG, Venutolo C, Yau PL, Convit A. Fitness, insulin sensitivity, and frontal lobe integrity in adults with overweight and obesity. Obesity. 2016;24(6):1283-9.

Chandarana K, Drew ME, Emmanuel J, Karra E, Gelegen C, Chan P, et al. Subject standardization, acclimatization, and sample processing affect gut hormone levels and appetite in humans. Gastroenterology. 2009;136(7):2115-26.

Cohen J. Statistical power analysis for the behavioral sciences. 1988. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates.

Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714-9.

Dang LC, Samanez-Larkin GR, Smith CT, Castrellon JJ, Perkins SF, Cowan RL, et al. FTO affects food cravings and interacts with age to influence age-related decline in food cravings. Physiol Behav. 2018;192:188-93.

Deighton K, Batterham RL, Stensel DJ. Appetite and gut peptide responses to exercise and calorie restriction. The effect of modest energy deficits. Appetite. 2014;81:52-9.

Deighton K, Karra E, Batterham RL, Stensel DJ. Appetite, energy intake, and PYY_{3-36} responses to energy-matched continuous exercise and submaximal high-intensity exercise. Appl Physiol Nutr Metab. 2013;38(9):947-52

Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol. 1974;37:247–8.

Douglas JA, King JA, Clayton DJ, Jackson AP, Sargeant JA, Thackray AE, et al. Acute effects of exercise on appetite, ad libitum energy intake and appetite-regulatory hormones in lean and overweight/obese men and women. Int J Obes. 2017;41(12):1737-44.

Dhurandhar NV, Schoeller D, Brown AW, Heymsfield SB, Thomas D, Sørensen TI, et al. Energy balance measurement: when something is not better than nothing. Int J Obes. 2015;39(7):1109-13.

Flint A, Gregersen NT, Gluud LL, Møller BK, Raben A, Tetens I, et al. Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: a meta-analysis of test meal studies. Br J Nutr 2007;98(1):17-25.

Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes. 2000;24(1):38–48.

Flom P, Cassell D. Stopping stepwise: Why stepwise and similar selection methods are bad, and what you should use. NESUG 2007 Proceedings: Statistics and data analysis.

Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889-94.

Gelman A, Pardoe I. Average predictive comparisons for models with nonlinearity, interactions, and variance components. Sociol Methodol. 2007;37(1):23-51.

Goltz FR, Thackray AE, Atkinson G, Lolli L, King JA, Dorling JL, et al. True interindividual variability exists in postprandial appetite responses in healthy men but is not moderated by the FTO genotype. J Nutr. 2019 [in press].

Goltz FR, Thackray AE, King JA, Dorling JL, Atkinson G, Stensel DJ. Interindividual responses of appetite to acute exercise: a replicated crossover study. Med Sci Sports Exerc. 2018;50(4):758-68.

Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000;279(3):909-13.

Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11-8.

Jackson AS, Pollock ML, Ward A. Generalized equations for predicting body density of women. Med Sci Sports Exerc.1980;12(3):175-81.

Jackson AS, Pollock ML. Generalized equations for predicting body density of men. Br J Nutr. 1978;40(3):497-504.

Karra E, O'Daly OG, Choudhury AI, Yousseif A, Millership S, Neary MT, et al. A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest. 2013;123(8):3539-51.

King JA, Deighton K, Broom DR, Wasse LK, Douglas JA, Burns SF, et al. Individual variation in hunger, energy intake, and ghrelin responses to acute exercise. Med Sci Sports Exerc. 2017;49(6):1219-28.

King NA, Caudwell PP, Hopkins M, Stubbs JR, Naslund E, Blundell JE. Dual-process action of exercise on appetite control: increase in orexigenic drive but improvement in meal-induced satiety. Am J Clin Nutr. 2009;90(4):921-7.

Kline RB. Beyond significance testing: Reforming data analysis methods in behavioral research. 2004. Washington, DC: American Psychological Association.

Kozey-Keadle S, Libertine A, Lyden K, Staudenmayer, J, Freedson, PS. Validation of wearable monitors for assessing sedentary behavior. Med Sci Sports Exerc. 2011;43(8):1561-7.

Le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006;147(1):3-8.

Le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA, Bloom SR. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab. 2005;90(2):1068-71.

MacLean PS, Blundell JE, Mennella JA, Batterham RL. Biological control of appetite: A daunting complexity. Obesity (Silver Spring). 2017;25;Suppl 1:S8-S16.

Magno FCCM, Guaraná HC, Fonseca ACP, Cabello GMK, Carneiro JRI, Pedrosa AP, et al. Influence of FTO rs9939609 polymorphism on appetite, ghrelin, leptin, IL6, TNFα levels, and food intake of women with morbid obesity. Diabetes Metab Syndr Obes. 2018;11:199-207.

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-50.

Marshall JA, Grunwald GK, Donahoo WT, Scarbro S, Shetterly SM. Percent body fat and lean mass explain the gender difference in leptin: analysis and interpretation of leptin in hispanic and non-hispanic white adults. Obes Res. 2000;8(8):543-52.

Melhorn SJ, Askren MK, Chung WK, Kratz M, Bosch TA, Tyagi V, et al. FTO genotype impacts food intake and corticolimbic activation. Am J Clin Nutr. 2018;107(2):145-54.

Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther. 2009;124(1):44-56.

Rosenbaum M, Leibel RL. Role of leptin in energy homeostasis in humans. J Endocrinol. 2014;223(1):T83-96.

Rostás I, Pótó L, Mátrai P, Hegyi P, Tenk J, Garami A, et al. In middle-aged and old obese patients, training intervention reduces leptin level: A meta-analysis. PLoS One. 2017;12(8):e0182801.

Senn S. Mastering variation: variance components and personalised medicine. Stat Med 2016;35:966–77.

Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87(1):240–4.

Siri WE. Body composition from fluid space and density. In Brozek J & Hanschel A (Eds.), Techniques for measuring body composition. 1961;223-44. Washington, DC: National Academy of Science.

Sonestedt E, Roos C, Gullberg B, Ericson U, Wirfält E, Orho-Melander M. Fat and carbohydrate intake modify the association between genetic variation in the FTO genotype and obesity. Am J Clin Nutr. 2009;90(5):1418-25.

Sondergaard E, Gormsen LC, Nellemann B, Vestergaard ET, Christiansen JS, Nielsen S. Visceral fat mass is a strong predictor of circulating ghrelin levels in premenopausal women. Eur J Endocrinol. 2009;160(3):375-9.

Speakman JR. The 'fat mass and obesity related' (FTO) gene: mechanisms of impact on obesity and energy balance. Curr Obes Rep. 2015;4(1):73-91.

Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO gene are associated with variation in energy intake, but not energy expenditure. Obesity. 2008;16(8):1961-5.

Steiger JH. Beyond the F test: Effect size confidence intervals and tests of close fit in the analysis of variance and contrast analysis. Psychol Methods. 2004;9(2):164-82

Stubbs RJ, Hughes DA, Johnstone AM, Rowley E, Reid C, Elia M, et al. The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings. Br J Nutr. 2000;84: 405–15.

Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707-9.

Yoshimoto A, Mori K, Sugawara A, Mukoyama M, Yahata K, Suganami T, et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002;13(11):2748-52.

Weise CM, Hohenadel MG, Krakoff J, Votruba SB. Body composition and energy expenditure predict ad-libitum food and macronutrient intake in humans. Int J Obes. 2014;38(2):243-51.

West J, Dahlqvist Leinhard O, Romu T, Collins R, Garratt S, Bell JD, et al. Feasibility of MR-based body composition analysis in large scale population studies. PLoS One. 2016;11(9):e0163332.

Whittingham MJ, Stephens PA, Bradbury RB, Freckleton RP. Why do we still use stepwise modelling in ecology and behaviour? J Anim Ecol. 2006;75(5):1182-9.